-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
(2020/07/24) The four biotech companies on NASDAQ are planning to IPO for more than $700 million; the listing has fallen from 37,000 to 1998 waterfall price cuts in just four years; and the gynaecological chinese traditional drug retail TOP10 is out! 500 million products into "explosive" Enway, thousands of gold ... (Click on the title, get the original text) "Medical Time 1" NASH field latest progress: Genfit termination phase III trial CymaBay clinical shelving release of non-alcoholic fatty hepatitis (NASH) has become the second most common cause of liver transplantation after chronic hepatitis C.
, the NASH market is now $40 billion, but no therapeutic drugs have been approved for sale.
headlines: NASH is still an attractive area.
" Seibai Blue" well-known pharmaceutical company pharmaceutical representative was investigated recently, the Communist Party of Hangzhou Xiaoshan District Discipline Inspection Commission public number "Xiaoshan Qingfeng" released: a well-known pharmaceutical enterprises, the former regional manager suspected of serious violations of the law, according to the Zhejiang Provincial Supervisory Commission, Hangzhou Municipal Supervision Commission designated jurisdiction, is currently under investigation by the Xiaoshan District Supervision Commission.
headlines: Medical anti-corruption remains a top priority.
the "Minnet.com" gynaecological traditional medicine retail TOP10 out of the oven! 500 million products into "explosive" Enway, thousands of gold ... With the development of society and the improvement of women's awareness of self-care, the retail market of traditional medicine in gynaecology has developed steadily.
-minnet data show that in recent years in China's urban retail pharmacies in the market for traditional drugs gynaecological drugs, gynecological drug treatment and gynaecological inflammatory drug has become the two main forces.
TOP20 manufacturers, Shanxi Guangyu Yuanguo Pharmaceutical, Zhuzhou Qianjin Pharmaceuticals, Li Shizhen Pharmaceutical Group, Shandong Step Shenzhou Pharmaceuticals, Sichuan Enwei Pharmaceuticals ranked in the top five, the total market share of nearly 30%.
headlines: TOP10 product sales are more than 100 million yuan.
" Hasa down the nasdaq with four biotech companies planning to IPO more than $700 million, many industries have been hit by big or small.
in the field of biotechnology and medicine, but there is a "counter-trend" scene.
, the well-known Silicon Valley Bank (SVB) released its investment and financing report for the first half of 2020, pointing out that well-known venture capital investors in the healthcare sector have raised nearly as much in the first half of 2019! In terms of IPOs, biotech and pharmaceutical companies have also been very active in recent weeks.
headline: Buck.
"E drug manager" listed only four years from 37,000 to 1998 waterfall price reduction behind what the enterprise experienced in fact, the listing in the short term has experienced the country talk and national varieties are not much, after the health insurance negotiations, enterprises through a sharp price reduction to seek the release effect, but if in the short term to experience a competition with generic drugs in the national collection, will be its expansion of the market and rapid release of the obstruction.
and Acetate Abitron suffered this embarrassment.
2016 listing sales, 2017 health care negotiations, 2019 recorded nearly 800 million sales but included in the national collection, 2020 and a "process bite gold", can be described as "a good play."
headlines: The effect of patent cliffs and national harvesting is so sudden and violent.
Dandelion was recalled July 22 for two batches of injections for cross-contamination, and the FDA website announced a recall of injections.
recall edaper stake in Fessenyuskabi, a long-established German company, was recalled because two batches of injectable products were contaminated with another active ingredient.
headlines: Potentially life-threatening.
.